古塞奇尤单抗治疗对肿瘤坏死因子抑制剂应答不佳的活动性银屑病关节炎患者的疗效与安全性:一项IIIb期随机对照研究(COSMOS)至一年的结果
COSMOS研究纳入285例对肿瘤坏死因子抑制剂(TNFi)应答不佳的活动性银屑病关节炎(PsA)患者,按2:1随机接受古塞奇尤单抗100 mg或安慰剂。第24周时古塞奇尤单抗组ACR20应答率44.4%,显著高于安慰剂组的19.8%,差异24.6%(95%CI 14.1至35.2),所有关键次要终点亦优效。至第56周安全性良好,未报告死亡或机会性感染。
要点
- 第24周古塞奇尤单抗组ACR20应答率44.4%,安慰剂组19.8%,差异24.6%(95%CI 14.1至35.2),多重校正后p<0.001。
- 古塞奇尤单抗在所有关键次要终点(HAQ-DI变化、ACR50、SF-36 PCS变化、PASI100)均优于安慰剂,多重校正后p<0.01。
- 古塞奇尤单抗组第48周ACR20应答率(无应答者填补)为58%,第24周应答者中>80%在第48周维持应答。
核心结论
- 古塞奇尤单抗显著改善对TNFi应答不佳的PsA患者的关节和皮肤表现及躯体功能。
- 至1年时显示出有利的获益-风险特征。
研究设计与样本
- IIIb期随机、对照研究(COSMOS),纳入285例活动性PsA(≥3个肿胀关节和≥3个压痛关节)且因应答不佳(疗效不足或不耐受)停用≤2种TNFi的成人患者。
- 患者按2:1随机接受皮下古塞奇尤单抗100 mg或安慰剂,第0周、第4周给药,之后每8周一次至第44周;安慰剂组患者在第24周交叉至古塞奇尤单抗。
- 主要终点(ACR20)和关键次要终点(HAQ-DI变化、ACR50、SF-36 PCS变化、PASI100)在第24周进行固定序列检验(双侧α=0.05);不良事件评估至第56周。
- 285例参与者中女性占52%,既往使用1种TNFi者占88%、2种者占12%;189例古塞奇尤单抗组中88%和96例安慰剂→古塞奇尤单抗组中86%的患者完成研究药物至第44周。
主要发现
- 第24周古塞奇尤单抗组ACR20应答率44.4%,安慰剂组19.8%,差异24.6%(95%CI 14.1至35.2),多重校正后p<0.001。
- 古塞奇尤单抗在所有关键次要终点均优于安慰剂(多重校正后p<0.01)。
- 古塞奇尤单抗组第48周ACR20应答率(无应答者填补)为58%;第24周应答者中>80%在第48周维持应答。
- 至第24周,189例古塞奇尤单抗随机组中严重不良事件/严重感染发生率为3.7%/0.5%,96例安慰剂随机组为3.1%/0%。
- 古塞奇尤单抗安全性特征至第56周相似,未报告死亡或机会性感染。
关键数值与推荐
- 主要终点:第24周ACR20应答率古塞奇尤单抗组44.4% vs 安慰剂组19.8%,差异24.6%(95%CI 14.1至35.2),多重校正后p<0.001。
- 关键次要终点:第24周HAQ-DI变化、ACR50、SF-36 PCS变化和PASI100,古塞奇尤单抗均优于安慰剂,多重校正后p<0.01(原文未报告各终点具体数值)。
- 第48周ACR20应答率(无应答者填补):古塞奇尤单抗组58%。
- 至第24周严重不良事件:古塞奇尤单抗随机组3.7%(189例中)vs 安慰剂随机组3.1%(96例中);严重感染:古塞奇尤单抗随机组0.5%(189例中)vs 安慰剂随机组0%(96例中)。
临床怎么用
- 对于因疗效不足或不耐受停用≤2种TNFi的活动性PsA患者,古塞奇尤单抗100 mg皮下给药(第0周、第4周,之后每8周一次)至第24周可显著提高ACR20应答率并改善关键次要终点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate efficacy and safety of guselkumab, an anti-interleukin-23p19-subunit antibody, in patients with psoriatic arthritis (PsA) with prior inadequate response (IR) to tumour necrosis factor inhibitors (TNFi). METHODS: Adults with active PsA (≥3 swollen and ≥3 tender joints) who discontinued ≤2 TNFi due to IR (lack of efficacy or intolerance) were randomised (2:1) to subcutaneous guselkumab 100 mg or placebo at week 0, week 4, then every 8 weeks (Q8W) through week 44. Patients receiving placebo crossed over to guselkumab at week 24. The primary (ACR20) and key secondary (change in HAQ-DI, ACR50, change in SF-36 PCS and PASI100) endpoints, at week 24, underwent fixed-sequence testing (two-sided α=0.05). Adverse events (AEs) were assessed through week 56. RESULTS: Among 285 participants (female (52%), one (88%) or two (12%) prior TNFi), 88% of 189 guselkumab and 86% of 96 placebo→guselkumab patients completed study agent through week 44. A statistically significantly higher proportion of patients receiving guselkumab (44.4%) than placebo (19.8%) achieved ACR20 (%difference (95% CI): 24.6 (14.1 to 35.2); multiplicity-adjusted p<0.001) at week 24. Guselkumab was superior to placebo for each key secondary endpoint (multiplicity-adjusted p<0.01). ACR20 response (non-responder imputation) in the guselkumab group was 58% at week 48; >80% of week 24 responders maintained response at week 48. Through week 24, serious AEs/serious infections occurred in 3.7%/0.5% of 189 guselkumab-randomised and 3.1%/0% of 96 placebo-randomised patients; the guselkumab safety profile was similar through week 56, with no deaths or opportunistic infections. CONCLUSION: Guselkumab significantly improved joint and skin manifestations and physical function in patients with TNFi-IR PsA. A favourable benefit-risk profile was demonstrated through 1 year. TRIAL REGISTRATION NUMBER: NCT03796858.
引用
- Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2021. PMID: 34819273. doi:10.1136/annrheumdis-2021-220991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。